Published in final edited form as:

Leukemia. 2020 January ; 34(1): 210–223. doi:10.1038/s41375-019-0540-7.

BCMA peptide engineered nanoparticles enhance induction and function of antigen-specific CD8⁺ cytotoxic T lymphocytes against multiple myeloma: Clinical applications

Joeun Bae^{1,2}, Neha Parayath³, Wenxue Ma⁴, Mansoor Amiji⁵, Nikhil Munshi^{1,2}, Kenneth Anderson^{1,2}

¹Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

²Harvard Medical School, Boston, Massachusetts, USA.

³Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

⁴University of California San Diego, San Diego, California, USA.

⁵Northeastern University, Boston, Massachusetts, USA.

Abstract

Objective: The purpose of these studies was to develop and characterize B-cell Maturation Antigen (BCMA)-specific peptide encapsulated nanoparticle formulations to efficiently evoke BCMA-specific CD8⁺ cytotoxic T lymphocytes (CTL) with poly-functional immune activities against multiple myeloma (MM).

Findings: Heteroclitic BCMA₇₂₋₈₀ [YLMFLLRKI] peptide encapsulated liposome or poly(lactic-co-glycolic acid) (PLGA) nanoparticles displayed uniform size distribution and increased peptide delivery to human dendritic cells which enhanced induction of BCMA-specific CTL. Distinct from liposome-based nanoparticles, PLGA-based nanoparticles demonstrated a gradual increase in peptide uptake by antigen-presenting cells, and induced BCMA-specific CTL with higher anti-tumor activities (CD107a degranulation, CTL proliferation, and IFN- γ /IL-2/TNF- α production) against primary CD138⁺ tumor cells and MM cell lines. The improved functional activities were associated with increased Tetramer⁺/CD45RO⁺ memory CTL, CD28 upregulation on Tetramer⁺ CTL, and longer maintenance of central memory (CCR7⁺ CD45RO⁺) CTL, with the highest anti-MM activity and less differentiation into effector memory (CCR7⁻ CD45RO⁺) CTL.

Conclusion: These results provide the framework for therapeutic application of PLGA-based BCMA peptide delivery system, rather than free peptide, to enhance the induction of BCMA-specific CTL with poly-functional Th1-specific anti-MM activities.

Corresponding author: Joeun Bae, Ph.D., Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, Phone: 617-632-5908, Fax: 617-632-2140, joeun_bae@dfci.harvard.edu.

Conflict of Interest:

No relevant conflicts of interest were disclosed by the authors.

A conflict of interest disclosure statement:

There is no conflict of interest to disclose.

Significance: These results demonstrate the potential clinical utility of PLGA nanotechnology-based cancer vaccine to enhance BCMA-targeted immunotherapy against myeloma.

Keywords

Nanomedicine-based Cancer Vaccine; Targeted Immunotherapy specific to BCMA

INTRODUCTION

Significant advances in cancer immunotherapy including immune checkpoint inhibition have achieved remarkable responses, changed the treatment paradigm, and improved patient outcome in many solid tumors. Chimeric antigen receptor (CAR) T-cell therapy has recently achieved great clinical response and has improved patient outcome in relapsed/refractory acute lymphocytic leukemia and diffuse large B cell lymphoma, leading to their FDA approval. However, current cellular therapies including CAR-T therapy require complex patient-specific protocols for engineering and expansion of effector cells, which are both labor-intensive and cost-ineffective.¹⁻⁴ To overcome these limitations, successful development of an off-the-shelf cancer vaccine would be beneficial to treat patients efficiently over individualized cellular-based vaccines. As an active-specific immunotherapy, cancer vaccine approaches have the potential to modulate the tumor microenvironment through dynamic interaction of various cell subsets in the patients, which contribute to antigen-presentation, T cells activation, effector cells functionality and the specific memory CTL development.^{5,6} With encouraging preclinical results, we are evaluating a multi-peptide vaccine targeting XBP-1, CD138 and CS1 in the patients with smoldering multiple myeloma and have detected the antigens-specific immune responses as increased Tetramer⁺/memory CD8⁺ CTL with higher IFN- γ /IL-2/TNF- α production. Moreover, combination of the multi-peptide vaccine with lenalidomide enhanced the induction of CD8⁺ CTL with Tetramer-positivity and Th-1-specific memory CD8⁺ CTL.⁷⁻¹⁰ To date, clinical efficacy of vaccines has been limited, at least in part due to the need for improved methods for tumor-associated antigen (TAA) delivery, stability, biodistribution, and presentation for T cell activation.¹¹⁻¹³

MM is a B-cell malignancy characterized by the clonal proliferation and accumulation of malignant plasma cells in the bone marrow, monoclonal protein in the serum and/or urine, and development of osteolytic bone lesions. Despite remarkable recent advances in treatment using novel therapeutics, MM remains incurable. BCMA, a member of the tumor necrosis factor (TNF) receptor superfamily and the receptor for binding of B cell activating factor (BAFF) and the proliferation-inducing ligand (APRIL),¹⁴⁻¹⁶ is a promising therapeutic target for development of an immunotherapy due to its restricted expression on MM and plasma cells along and its critical role in promoting tumor cell growth, survival and drug resistance. At present, BCMA is being targeted by several immunotherapeutic strategies including monoclonal antibodies (mAbs), immunotoxins, bispecific T-cell engagers, and adoptive immunotherapy (e.g. CAR-T), with promising early results in the clinic. However, there remains significant need to improve BCMA targeted active-specific immunotherapy capable of inducing highly effective and long-lasting MM-specific CTL with a favorable therapeutic index.

We recently identified a novel immunogenic heteroclitic BCMA₇₂₋₈₀ [YLMFLLRKI] peptide derived from human BCMA protein and reported its potential therapeutic application as a vaccine and adoptive T cell therapy.¹⁷ The engineered heteroclitic BCMA₇₂₋₈₀ [YLMFLLRKI] peptide has a strong HLA-A2 binding affinity and stability with improved immunogenicity from its native BCMA₇₂₋₈₀ [VLMFLLRKI] peptide and induces robust BCMA-specific memory CD8⁺ CTL responses against MM cells. In this study, we have developed a strategy to further enhance BCMA-specific CTL generation and their anti-tumor activities, in order to achieve clinically significant responses. We define a nanoparticle-based BCMA delivery technology in which the heteroclitic BCMA₇₂₋₈₀ [YLMFLLRKI] peptide is encapsulated in nanovehicles, either PLGA or liposome, to improve antigen delivery and presentation, thereby inducing more robust poly-functional BCMA-specific CD8⁺ CTL responses against MM than vaccination with peptide alone.

METHODS

Cell lines and Reagents

The MM cell lines were obtained from ATCC (Manassas, VA) and the T2 cell line was provided by Dr. J. Mollidrem (University of Texas M. D. Anderson Cancer Center, Houston, TX). Recombinant human GM-CSF, IL-2, IL-4, IFN- α and TNF- α were purchased from Immunex (Seattle, WA) or R&D Systems (Minneapolis, MN). Heteroclitic BCMA₇₂₋₈₀ [YLMFLLRKI] peptide, unlabeled or FITC-labeled, were synthesized by standard fmoc (9-fluorenylmethyl-oxycarbonyl) chemistry, purified to > 98% using reverse-phase chromatography and validated by mass-spectrometry for molecular weight (Biosynthesis, Lewisville, TX). Tetramer-PE specific to the heteroclitic BCMA₇₂₋₈₀ peptide was synthesized by MBL International Corporation (Woburn, MA).

Formulation and characterization of heteroclitic BCMA₇₂₋₈₀ peptide encapsulated PLGA or liposome nanoparticles

A double emulsion-solvent technique was used to formulate PLGA (molecular weight 23,000; Birmingham Polymers, Birmingham, AL) nanoparticles loaded with immunogenic heteroclitic BCMA₇₂₋₈₀ [YLMFLLRKI] peptide. Poly(vinyl alcohol) (PVA) (Sigma-Aldrich, St Louis, MO) was used to stabilize the emulsion, as previously described¹⁸ with some modifications. Following formulation of the PLGA formulation, the diameter and surface charge was measured using a Zetasizer Nano-ZS90 (Malvern Instruments; Westborough, MA) dynamic light scattering instrument. To evaluate PLGA-nanoparticle structure, the lyophilized powder was visualized under a scanning electron microscope (SEM) (S-4800; Hitachi, Schaumburg, IL) at the magnification of 50X. For BCMA peptide encapsulated liposome formulation, liposome lipid bilayer was prepared with a mixture of 3 mM Cholesterol (MW = 386.654), 5 mM DOPC (MW = 786.113), and 5 mM DOTAP (MW = 698.542) (Avanti Polar, Alabaster, AL) in chloroform (Sigma-Aldrich) and evaporated using a rotary evaporator (RV10 IKA; Neobits, Santa Clara, CA) to yield a thin lipid film. The lipid film was subjected to overnight vacuum drying to remove any residual organic solvent. The next day, peptide dissolved in sodium phosphate buffer (dibasic; pH 11) and 1% DMSO (Sigma-Aldrich) was used to hydrate the lipid film using 10X freeze-thaw cycles, followed by probe sonication on ice and recovered by ultracentrifugation. Malvern's Zetasizer

dynamic light scattering instrumentation was used to determine the liposome diameter. Transmission electron microscopy (TEM) (JEM-1000, JEOL, Tokyo, Japan) was utilized to characterize the surface morphology of the BCMA peptide-loaded liposome after applying 2% uranyl acetate stain at the magnification of 20,000X.

Quantification of BCMA peptide encapsulation in PLGA or liposome nanoparticles

The BCMA peptide encapsulation in nanoparticles was measured using the Quantitative Fluorometric Peptide Assay Kit (Thermo Fisher) per the manufacturer's instruction. The fluorescence was measured using a spectrophotometer (Molecular Devices, San Jose, CA) at 390 nm Excitation and 475 nm Emission wave lengths for the peptide quantification.

Evaluation of BCMA peptide-encapsulated nanoparticles for peptide uptake by dendritic cells

Monocyte-derived dendritic cells (DC) were generated as described previously.⁷⁻⁹ Immature DC (1×10^6 cells/well) were pulsed with free BCMA peptide-FITC or the peptide-FITC encapsulated nanoparticles in the presence of human $\beta 2$ -microglobulin (3 μ g/ml) and incubated at 37°C. Cells were washed, fixed in 2% paraformaldehyde, acquired using a LSRII Fortessa™ flow cytometer (Becton Dickinson (BD), San Jose, CA). The level of peptide loading was analyzed in a time-dependent manner using FACS DIVA™ v8.0 (BD) or FlowJo v10.0.7 (Tree star, Ashland, OR) software. The peptide uptake was also imaged by confocal microscopy (Nikon, Tokyo, Japan), upon fixation of the cells with 2% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) and counter-stained with 300 nM DAPI (Sigma-Aldrich) to identify cell nuclei.

Generation of heteroclitic BCMA₇₂₋₈₀ peptide-specific CTL

Heteroclitic BCMA₇₂₋₈₀ peptide [YLMFLLRKI]-specific CTL (BCMA-specific CTL) were generated *ex vivo* by repeated stimulation of peripheral blood mononuclear cells (PBMC) isolated from six different HLA-A2⁺ normal donors with (1) free BCMA peptide, (2) BCMA peptide encapsulated PLGA (PLGA/peptide) or (3) BCMA peptide encapsulated liposome (liposome/peptide). The BCMA-specific effector cells were cultured in DMEM supplemented with 10% human AB serum (BioWhittaker) and examined after each cycle of weekly stimulation for a total of 4 or 5 cycles.

Isolation of Primary CD138⁺ cells from Bone Marrow Mononuclear Cells of MM Patients

Primary CD138⁺ cells were isolated from bone marrow mononuclear cells obtained from HLA-A2⁺ and HLA-A2⁻ MM patients using RoboSep® CD138 positive immunomagnetic selection technology (StemCell Technologies), after appropriate informed consent.

Phenotypic characterization of BCMA-specific CTL induced with heteroclitic BCMA₇₂₋₈₀ peptide encapsulated nanoparticles or free peptide

BCMA-CTL were evaluated for antigen-specific Tetramer⁺ memory CTL and CD28 expression by flow cytometry. In brief, following Live/Dead-Aqua staining, BCMA-CTL were stained with heteroclitic BCMA₇₂₋₈₀ specific Tetramer-PE and fluoroconjugated

mAbs specific to surface antigens. Lastly, cells were washed, fixed in 2% paraformaldehyde, and analyzed by flow cytometry.

Evaluation of anti-myeloma activities of BCMA-specific CTL induced with heteroclitic BCMA₇₂₋₈₀ peptide encapsulated nanoparticles or free peptide

Proliferation of CFSE (Molecular Probes) labeled BCMA-specific CTL (CD8⁺ gated) was measured after co-culture with irradiated myeloma cells. On days 3-6 of co-culture, the cells were stained with specific mAbs, and acquired by flow cytometry. To measure anti-tumor activities, BCMA-CTL were mixed with the respective target in the presence of CD107a mAb. After 1 hour of co-culture, Brefeldin A and Monensin (BD) were added and cultures were incubated for an additional 5 hours at 37°C. Cells were harvested, stained with Live/Dead-Aqua and fluorochrome conjugated mAbs, fixed/permeabilized, and stained intracellularly with specific mAb against IFN- γ , IL-2 or TNF- α , acquired using a LSRII Fortessa™ flow cytometer (BD) and analyzed using FACS DIVA™ v8.0 (BD) or FlowJo v10.0.7 (Tree star, Ashland, OR) software

Statistical Analyses

Summary results are presented as the mean $\pm$ SE. Groups were compared using unpaired Student's t-test. Differences were considered significant when $*p < 0.05$.

RESULTS

Characterization and quantification of heteroclitic BCMA₇₂₋₈₀ peptide encapsulated nanoparticles

The size, zeta-potential and/or polydispersity index (PDI) of PLGA- or liposome-nanoparticles, with or without heteroclitic BCMA₇₂₋₈₀ [YLMFLLRKI] peptide, were measured using dynamic light scattering properties. Peptide loaded-PLGA (PLGA/peptide) (257 ± 11.53 nm; N=3) were slightly smaller than the blank PLGA (309 ± 4.01 nm; N=3), which can be attributed to a close interaction between PLGA co-polymer and the peptide (Figure 1A). The surface charge and zeta potential were measured as an important criteria for cellular uptake of peptide. Blank PLGA and PLGA/peptide had a near neutral zeta-potential, -0.66 ± 0.25 mV and -1.16 ± 0.18 mV, respectively. The peptide (positively charged at pH 7) would form the core of nanoparticles; while the near neutral surface charge is due to interaction with PLGA polymer, resulting in an increased stability due to a larger electrostatic repulsion between the nanoparticles. To evaluate size distribution, the blank PLGA or PLGA/peptide were sputter coated with gold/palladium and imaged using a scanning electron microscope under 20 kV at the magnification of 50X. The PDI of PLGA/peptide (0.2) was similar to blank PLGA, which indicates uniform size distribution (Figure 1A). The BCMA peptide loaded-liposome formulation (liposome/peptide) had a size distribution of 172 ± 0.73 d.nm (N=3) as measured using a transmission electron microscope, with a PDI of 0.20 ± 0.01 , reflecting uniform size distribution in the formulated product (Figure 1B). Next, peptide loading and encapsulation efficiency was evaluated with the Quantitative Fluorometric Peptide Assay, using a spectrophotometer at an Excitation wave length at 390 nm and an Emission wave length at 475 nm. The peptide encapsulation efficiency (%), which indicates the percentage of peptide loaded in PLGA or liposome over

the initial amount of loaded peptide, was $51 \pm 1.15\%$ and $49 \pm 1.32\%$, respectively (Figure 1C; N=3).

Enhanced BCMA peptide uptake by dendritic cells upon nanoparticle encapsulation

BCMA peptide uptake was evaluated after pulsing immature dendritic cells with free peptide-FITC, PLGA/peptide-FITC or liposome/peptide-FITC by flow cytometry. A higher level of peptide uptake ($*p < 0.05$) was detected for the encapsulated in either type of nanoparticles as compared to the free peptide, following a short (30 minutes - 2 hour, Figure 2A) or longer (1 – 18 hour, Figure 2B; N=3) duration of peptide pulsing. Between the two different types of formulations, liposome/peptide showed a faster and higher efficiency of uptake than PLGA/peptide, which demonstrated a gradual increase in peptide loading over time (Figures 2A, 2B). In addition, confocal microscopy (magnitude: 10X) showed a higher peptide uptake with PLGA/peptide as compared to free peptide (Figure 2C), confirming that the nanoparticles formulation enhances BCMA peptide uptake by dendritic cells. Thus, these results demonstrate the beneficial effect of both types of nanoparticles to enhance the peptide loading efficiency to antigen-presenting cells, which is a crucial step prior to triggering development of antigen-specific CTL.

Increased poly-functional immune responses by BCMA-specific CTL generated with peptide-encapsulated nanoparticles against myeloma cells

Free BCMA peptide, PLGA/BCMA peptide or liposome/BCMA peptide was used to generate the BCMA peptide-specific CTL from six different HLA-A2⁺ normal donors to evaluate their anti-myeloma activities. The highest levels of anti-tumor activity were observed with PLGA/peptide-CTL as shown by increased CD107a degranulation (Figure 3A), IFN- γ production (Figure 3B), IL-2 and TNF- α production (Supplemental Fig. 1, Fig. 2) against HLA-A2⁺ U266 myeloma cells but not against MHC mis-matched HLA-A2⁻ RPMI myeloma cells. Further evaluations were performed using BCMA-CTL generated from additional three HLA-A2⁺ individuals and the results confirm the highest anti-myeloma activities ($*p < 0.05$) against HLA-A2⁺ BCMA^{++ (high)} U266 and HLA-A2⁺ BCMA^{+(low)} McCAR, but not against MHC mis-matched BCMA⁺ RPMI cells by PLGA/peptide-CTL (Figure 3C). The anti-myeloma activities of liposome/peptide-CTL were lower than PLGA/peptide-CTL but were greater than free peptide BCMA-CTL. These results indicate a robust generation of BCMA-specific CTL by PLGA/peptide as evidenced by their higher poly-functional activities against MM cell lines in an HLA-A2 restricted manner.

The highest anti-tumor activity by BCMA-specific CTL generated with PLGA/peptide against primary CD138⁺ tumor cells from MM patients

BCMA-specific CTL were further evaluated for their anti-myeloma activities against primary CD138⁺ tumor cells from newly diagnosed multiple myeloma patients. Background level of activity was measured in the BCMA-CTL in the absence of target cells (Supplemental Fig. 3). However, PLGA/peptide-CTL demonstrated higher anti-MM activities against primary CD138⁺ tumor cells from HLA-A2⁺ MM patients (patients #1 or #2) as compared to liposome/peptide-CTL and free peptide-CTL (Figure 4A, Figure 4B). Furthermore, BCMA-specific CTL generated from three additional HLA-A2⁺ individuals confirmed the different degree of anti-MM activities; Significantly ($*p < 0.05$) higher anti-

myeloma activities were induced with peptide encapsulated nanoparticles (PLGA/peptide > liposome/peptide) than free peptide against CD138⁺ primary tumor cells from HLA-A2⁺ MM patients (patients #3 or #4), but not against HLA-A2⁻ MM patients (Figure 4C; N=3). These results further indicate that BCMA peptide encapsulation in nanoparticles, especially PLGA, effectively induce robust BCMA-specific CTL activities against tumor cells from HLA-A2⁺ myeloma patients.

Increased BCMA-specific Tetramer⁺ CTL with CD28 upregulation in PLGA/peptide-CTL associated with BCMA peptide-specific Th1 cytokines production and proliferation

To better characterize the anti-myeloma activities of BCMA-specific CTL, we evaluated the proportion of specific Tetramer⁺ cells, CD28 costimulatory molecule expression and their immune functional activities in response to specific heteroclitic BCMA₇₂₋₈₀ peptide stimulation. PLGA/peptide-CTL displayed induced CD28 upregulation (32%) compared to free/peptide-CTL (16%) within the gated CD8⁺ T cells and also showed a higher frequency (2.1 fold increase) of Tetramer⁺ cells than the free peptide-CTL (Figure 5A, Lower panel). Furthermore, the BCMA-specific Tetramer⁺ cells within the PLGA/peptide-CTL, not Tetramer⁻ cells, showed an increased proportion of CD28⁺⁺ bright cells (PLGA/peptide-CTL: 52% vs. free peptide-CTL: 30%). Next, both BCMA-CTL were evaluated for their proliferation and Th1-type cytokine production in response to specific heteroclitic BCMA₇₂₋₈₀ peptide stimulation. PLGA/peptide-CTL (25-69%) consistently displayed a higher CD8⁺ T cell proliferation than free peptide CTL (11-33%) in response to specific the BCMA peptide in a time-dependent manner (Figure 5B). In contrast, control T cells obtained upon stimulation with blank PLGA showed minimal proliferation (CD8⁺ gated) in response to BCMA peptide on Day 3, 4 or 5 of culture (0 - 4%). In addition, increased IFN- γ production was detected in the PLGA/peptide-CTL (34% - 61%) compared with free peptide-CTL (32% - 42%) and the difference continued to increase with longer stimulation with the specific heteroclitic BCMA₇₂₋₈₀ peptide (Day 4 > Day 2) (Figure 5C). These results demonstrate enhanced BCMA-specific activities for PLGA/peptide-CTL than free peptide-CTL as directly evidenced by increased Tetramer⁺ CTL and CD28 co-stimulatory signal expression, CD8⁺ CTL proliferation and IFN- γ production.

Enhanced myeloma-specific CD8⁺ T cell proliferation and memory cells development by stimulation with PLGA/peptide

PLGA/peptide-CTL demonstrated a gradual increase in CD8⁺ T cell proliferation in response to HLA-A2⁺ U266 myeloma cells, which was higher than the proliferation of free peptide-CTL. Control PBMC stimulated with blank PLGA displayed minimal proliferation (Figure 6A), which confirms that PLGA itself is inert and can be used as a peptide delivery vehicle to induce antigen-specific CTL. The PLGA/peptide-CTL were further characterized for antigen-specific memory T cell development upon each round of stimulation. The development of CD45RO⁺ memory CTL occurred gradually after each round of heteroclitic BCMA₇₂₋₈₀ peptide stimulation. In comparison, CTL generated with PLGA/peptide contained a higher proportion of CD45RO⁺ memory cells than free peptide-CTL as measured post 2 and 4 cycles of BCMA stimulation (Figure 6B; N=3) (Supplemental Fig. 4). Overall, the PLGA/peptide-CTL displayed higher frequencies of the central memory (CM: CCR7⁺ CD45RO⁺) and effector memory (EM: CCR7⁻ CD45RO⁺) CTL subsets than

free peptide-CTL. Of note, the PLGA/peptide-CTL also retained a higher proportion of CTL within the CM subset without further differentiation into EM after 5 cycles of stimulation (Figure 6C). These results provide additional evidence of the therapeutic potential of heteroclitic BCMA₇₂₋₈₀ peptide encapsulated PLGA nanoparticles to effectively modulate antigen-specific memory CTL generation and maintenance with a high proportion of BCMA-specific central memory CTL subset.

Robust anti-myeloma activity by BCMA-specific central memory CTL induced with PLGA/peptide

BCMA-specific CTL were further evaluated to identify the specific memory subsets having the highest immune functional activities against myeloma. The highest level of CD107a degranulation was consistently detected with the CM subset in PLGA/BCMA-CTL against HLA-A2⁺ myeloma cells (Figure 7A). Importantly, both CM and EM subsets of PLGA/peptide-CTL demonstrated higher anti-tumor activity against HLA-A2⁺ U266 cells than the respective subsets from free peptide-CTL. Another key functional response assessed was Th1 cytokine production in response to myeloma. Consistent with degranulation, a higher level of IFN- γ production was detected within the CM subset than the EM subset of the BCMA-CTL and the memory CTL activity was increased to a greater extent in the PLGA/peptide-CTL (Figures 7B). Overall, the CM subset consistently displayed significantly ($p < 0.05$) higher CD107a degranulation and Th1-type cytokine (IFN- γ , IL-2, TNF- α) production as compared to the EM subset in response to myeloma cells in an HLA-A2 restricted manner and the highest overall anti-MM activities were observed in the PLGA/peptide-CTL (Figure 7C; N=3). These results further demonstrate that heteroclitic BCMA₇₂₋₈₀ peptide encapsulated in PLGA nanoparticles induce a more robust myeloma-specific CTL than free BCMA peptide, as evidenced by their efficient induction and maintenance of highly functional memory CTL against myeloma.

DISCUSSION

Cancer vaccines targeting well-characterized TAA for treatment and prevention remain a highly innovative therapeutic approach with distinct advantages over other immunotherapies. This approach has the potential to induce long-lasting durable anti-tumor T cell immune responses and may overcome obstacles to widespread adoption of CAR-T therapy including high costs of complex *ex vivo* engineering and expansion, development of resistance through tumor-antigen loss, and lack of sustained memory CTL-specific anti-tumor activities.^{19,20} Unlike CAR-T therapy which provides a uniform non-renewable effector T cell pool, cancer vaccines induce a dynamic pool of effector and memory T cells that provide tumor-specific immunity through *in vivo* development of Th1-specific responses.^{21,22} In addition, unlike commonly used treatments or CAR-T therapy which can induce significant toxicities in patients, vaccines induce endogenous immune responses and TAA-specific memory function with few adverse events.²³⁻²⁵

With this rationale, we and others have developed methods to improve immune and clinical response to cancer vaccines. Specifically, we are continuously identifying TAA uniquely expressed on CD138⁺ tumor cells from newly diagnosed MM patients (N=1,254) and are

developing protocols to target the novel antigens, as individually or as a multi-peptide cocktail. To date, we have demonstrated the immunogenicity of XBP1, CD138 and CS1-specific peptides and have shown that immunization with the XBP1, CD138 and CS1-specific immunogenic peptides cocktail can induce myeloma-specific memory CTL having Th1 type immune responses in smoldering myeloma patients.⁷⁻¹⁰ Since then, we continue to develop clinical protocols to determine whether vaccination in combination with adjunct therapies, lenalidomide, checkpoint inhibitor, or histone deacetylase inhibitor can enhance the extent and durability of the vaccine-specific responses. Most recently, we reported on a novel immunogenic heteroclitic BCMA₇₂₋₈₀ [YLMFLLRKI] peptide derived from human BCMA with enhanced HLA-A2 binding affinity, stability, and immunogenicity compared to the native BCMA₇₂₋₈₀ [VLMFLLRKI] peptide.¹⁸ Importantly, the heteroclitic BCMA₇₂₋₈₀ peptide induces robust BCMA-specific memory CD8⁺ CTL responses with anti-tumor activities and is being incorporated into a vaccine plus adoptive cellular immunotherapy in myeloma patients. In addition to identifying novel targets, we are also developing improved cancer vaccine delivery systems to facilitate uptake and suitable antigen release by dendritic cells to optimize the peptide presentation required for effective generation of antigen-specific CTL with poly-functional anti-MM activities. To that extent, we have exploited the remarkable progress in nanomedicines over the past decade to develop a potential delivery system.²⁶⁻²⁹ Specifically, advanced nanoparticles construct of polymeric micelles/vesicles or lipidic nanoparticles have enabled successful *in vivo* delivery of various small molecules, nucleic acids (mRNA, siRNA, DNA), and therapeutic proteins, for a biomedical and therapeutic applications.³⁰⁻³² For example, nanoparticle-based therapies can augment tissue-specific drug delivery and promote controlled drug release due to increased surface area to drug volume ratios.³³⁻³⁶ Importantly, the therapeutic efficacy of nanoparticles-based therapy is highly dependent on the type of nanocarriers and their specific performance characteristics.

Here we report our findings using two different nanoparticles formulations encapsulating immunogenic heteroclitic BCMA₇₂₋₈₀ [YLMFLLRKI] peptide that efficiently deliver and induce myeloma-specific CD8⁺ CTL. Our chosen PLGA- and lipid-based nanoparticle delivery constructs have previously shown *in vivo* compatibility and biodegradability and are approved for human usage by the US Food and Drug Administration (FDA), making them ideal for clinical application.³⁷⁻⁴¹ In these studies, we specifically demonstrate improved efficiency for encapsulated PLGA or liposome nanoparticles to deliver our immunogenic BCMA peptide to human dendritic cells, as compared to free peptide alone. Both nanoparticle constructs exhibit uniform size distribution, had similar efficiency of BCMA peptide encapsulation and provide improved peptide delivery to dendritic cells. Interestingly, the kinetics of peptide loading to dendritic cells and subsequent induction of BCMA-specific CD8⁺ CTL were distinct between the two formulations; PLGA/peptide required a longer period of time (18 hours) for maximum peptide loading, while liposome-nanoparticles/peptide achieved the maximum loading in just 30 minutes. Distinct from the loading kinetics, the PLGA/peptide induced a more effective BCMA-specific CTL characterized by their robust poly-functional anti-myeloma activities (CD107a degranulation-based cytotoxicity and Th1-type cytokine production) than the liposome/peptide. Based on these observations, we hypothesize that “gradual” antigen uptake and delivery of immunogenic

peptide by dendritic cells to naïve CD8⁺ T cells will result in a more efficient induction of the antigen-specific CTL with a greater level of anti-tumor activities. Other investigators have reported that nanoparticles-based cancer vaccines evoke both humoral and cellular T-cell responses⁴²⁻⁴⁴, but these nanoparticle-based cancer vaccines have not achieved prolonged extent and duration of ant-tumor responses in patients and have not shown clinical benefit to date. However, it is important to note that the clinical trials evaluated nanoparticle-based cancer vaccines utilized mainly lipid or liposome as the nano-vehicle.⁴⁵⁻⁴⁸ In comparison, PLGA-based nanoparticles have been evaluated as delivery vehicles for therapy, mainly in preclinical models, for diseases such as hepatitis B, chlamydia, malaria, leishmaniasis, tuberculosis, toxoplasmosis; they have shown an excellent safety profile and biodegradability as a controlled-release system,⁴⁹⁻⁵⁴ providing further rationale for their clinical development in cancer therapies. Here, we demonstrate encouraging results using PLGA as a delivery system and propose BCMA peptide encapsulated PLGA-nanoparticles as an effective strategy to improve the peptide delivery to antigen-presenting cells and the subsequent enhancement in the development of BCMA-specific CTL with robust anti-myeloma activities. Additionally, the results presented here collaborates prior reports showing that PLGA as a carrier confers protection of loaded antigen against proteolytic degradation, prolongs plasma half-life and promotes long-term antigen release⁵⁵⁻⁵⁶ and is an effective delivery vehicle for induction of effective and long-lasting immunity, thereby potentially avoiding or reducing the multiple administrations required in conventional vaccine approaches.⁵⁷⁻⁶⁰

In summary, we report on novel immunogenic heteroclitic BCMA₇₂₋₈₀ peptide encapsulated nanoparticle delivery systems that promote generation and maintenance of highly functional myeloma-specific CTL. Based on these results presented here, we propose to use PLGA nanoparticles as the optimal delivery system for heteroclitic BCMA₇₂₋₈₀ peptide. These studies provide the rationale for immunotherapeutic strategies and framework for nanomedicine-based cancer vaccine and adoptive cellular therapy in which PLGA-based peptide vaccination induces antigen-specific memory CTL *in vivo*, which are then harvested, expanded *ex vivo* in the presence of peptide and re-infused to patients; nanoparticle-based cancer vaccination can then be used as needed to maintain the memory CTL activities against myeloma.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENT

The authors acknowledge the Miriam and Sheldon G Adelson Medical Research Foundation. This work was also supported in part by grants from the National Institutes of Health Grants Special Program in Oncology Research Excellence (SPORE) P50 100707, RO1 CA 207237, and RO1 CA 050947. Dr. Kenneth C. Anderson is an American Cancer Society Clinical Research Professor.

Financial support, including the source and number of grants, for each author:

NIH Special Program in Oncology Research Excellence (SPORE) P50 100707, RO1 CA 207237, and RO1 CA 050947.

REFERENCES

1. Miliotou AN, Papadopoulou LC. CAR T-cell Therapy: A New Era in Cancer Immunotherapy. *Curr Pharm Biotechnol* 2018; 19: 5–18. [PubMed: 29667553]
2. Legut M, Sewell AK. Designer T-cells and T-cell receptors for customized cancer immunotherapies. *Curr Opin Pharmacol* 2018; 41: 96–103. [PubMed: 29852403]
3. Ping Y, Liu C, Zhang Y. T-cell receptor-engineered T cells for cancer treatment: current status and future directions. *Protein Cell* 2018; 9: 254–266. [PubMed: 28108950]
4. Salter AI, Pont MJ, Riddell SR. Chimeric antigen receptor-modified T cells: CD19 and the road beyond. *Blood* 2018; 131: 2621–2629. [PubMed: 29728402]
5. Curran MA, Glisson BS. New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation. *Annu Rev Med* 2018; doi:10.1146/annurev-med-050217-121900.
6. Chamani R, Ranji P, Hadji M, Nahvijou A, Esmati E, Alizadeh AM. Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis. *Eur J Pharmacol* 2018; 831: 87–93. [PubMed: 29753042]
7. Bae J, Carrasco R, Lee AH, Prabhala R, Tai YT, Anderson KC et al. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. *Leukemia* 2011; 25: 1610–1619. [PubMed: 21660045]
8. Bae J, Tai YT, Anderson KC, Munshi NC. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. *Br J Haematol* 2011; 155: 349–361. [PubMed: 21902685]
9. Bae J, Song W, Smith R, Daley J, Tai YT, Anderson KC et al. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. *Br J Haematol* 2012; 157: 687–701. [PubMed: 22533610]
10. Nooka AJ, Wang M, Yee AJ, Kaufman J, Bae J, Peterkin D et al. Safety and Immunogenicity of PVX-410 Vaccine ± lenalidomide in smoldering multiple myeloma. *JAMA Oncology* 2018; 8 16:e183267.
11. Tran T, Blanc C, Granier C, Saldmann A, Tanchot C, Tartour E. Therapeutic cancer vaccine: building the future from lessons of the past. *Semin Immunopathol* 2018; doi:10.1007/s00281-018-0691-z.
12. Scharping NE, Delgoffe GM. Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. *Vaccines (Basel)* 2016; 4.pii:E46. [PubMed: 27929420]
13. Strauss J, Madan RA, Gulley JL. Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. *Expert Opin Biol Ther* 2016; 16: 895–901. [PubMed: 27010190]
14. Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. *Blood* 2004; 103: 3148–3157. [PubMed: 15070697]
15. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. *J Exp Med* 2004; 199: 91–98. [PubMed: 14707116]
16. Coquery CM, Erickson LD. Regulatory roles of the tumor necrosis factor receptor BCMA. *Crit Rev Immunol* 2012; 32: 287–305. [PubMed: 23237506]
17. Bae J, Samur M, Richardson P, Munshi NC, Anderson KC. Selective Targeting of Multiple Myeloma by B cell Maturation Antigen (BCMA)-specific Central Memory CD8⁺ Cytotoxic T Lymphocytes: Immunotherapeutic Application in Vaccination and Adoptive Immunotherapy. *Leukemia* 2018; Manuscript Accepted.
18. Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. *Int J Cancer* 2004; 112: 335–340. [PubMed: 15352049]
19. Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. *Nat Rev Clin Oncol* 2018; 15: 31–46. [PubMed: 28857075]
20. O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrisette JD et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces

adaptive resistance in patients with recurrent glioblastoma. *Sci Transl Med* 2017; 9.pii:ea00984. [PubMed: 28724573]

21. Parvizpour Sepideh, Razmara Jafar, Omidi Yadollah. Breast cancer vaccination comes to age: impacts of bioinformatics. *Bioimpacts* 2018; 8: 223–235. [PubMed: 30211082]
22. Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. *Clin Cancer Res* 2013; 19: 4801–4815. [PubMed: 23838316]
23. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. *Nat Rev Clin Oncol* 2018; 15: 47–62. [PubMed: 28925994]
24. Kenderian SS, Porter DL, Gill S. Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. *Biol Blood Marrow Transplant* 2017; 23: 235–246. [PubMed: 27638367]
25. Schwarzbach MA, Witzens-Harig M. Cellular Immunotherapy in B-Cell Malignancy. *Oncol Res Treat* 2017; 40: 674–681. [PubMed: 29065420]
26. Buddolla AL, Kim S. Recent insights into the development of nucleic acid-based nanoparticless for tumor-targeted drug delivery. *Colloids Surf B Biointerfaces* 2018; 172: 315–322. [PubMed: 30176511]
27. Deshantri AK, Varela Moreira A, Ecker V, Mandhane SN, Schiffelers RM, Buchner M et al. Nanomedicines for the treatment of hematological malignancies. *J Control Release* 2018; 287: 194–215. [PubMed: 30165140]
28. Iqbal J, Abbasi BA, Ahmad R, Mahmood T, Ali B, Khalil AT et al. Nanomedicines for developing cancer nanotherapeutics: from benchtop to bedside and beyond. *Appl Microbiol Biotechnol* 2018; 102: 9449–9470. [PubMed: 30219952]
29. Tabassum N, Verma V, Kumar M, Kumar A, Singh B. Nanomedicine in cancer stem cell therapy: from fringe to forefront. *Cell Tissue Res* 2018; doi:10.1007/s00441-018-2928-5.
30. Zhang Y, Zhang P, Zhu T. Ovarian carcinoma biological nanotherapy: Comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery. *Biomed Pharmacother* 2018; 109: 475–483. [PubMed: 30399584]
31. Desfrancois C, Auzély R, Texier I. Lipid Nanoparticles and Their Hydrogel Composites for Drug Delivery: A Review. *Pharmaceuticals (Basel)* 2018; 11.pii:E118.doi:10.3390/ph11040118. [PubMed: 30388738]
32. Hong SJ, Ahn MH, Lee YW, Pal S, Sangshetti J, Arote RB. Biodegradable Polymeric Nanocarrier-Based Immunotherapy in Hepatitis Vaccination. *Adv Exp Med Biol* 2018; 1078: 303–320. [PubMed: 30357630]
33. Aftab S, Shah A, Nadhman A, Kurbanoglu S, Aysil Ozkan S, Dionysiou DD et al. Nanomedicine: An effective tool in cancer therapy. *Int J Pharm* 2018; 540: 132–149. [PubMed: 29427746]
34. Aw MS, Paniwnyk L. Overcoming T. gondii infection and intracellular protein nanocapsules as biomaterials for ultrasonically controlled drug release. *Biomater Sci* 2017; 5: 1944–1961. [PubMed: 28776612]
35. Bayford R, Rademacher T, Roitt I, Wang SX. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review. *Physiol Meas* 2017; 38: R183–R203. [PubMed: 28480874]
36. Tang Q, Yu B, Gao L, Cong H, Song N, Lu C. Stimuli Responsive Nanoparticles for Controlled Anti-cancer Drug Release. *Curr Med Chem* 2018; 25: 1837–1866. [PubMed: 29332566]
37. Jahan ST, Sadat SM, Haddadi A. Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine. *Int J Nanomedicine* 2018; 13: 367–386. [PubMed: 29391795]
38. Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR et al. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. *Biomaterials* 2018; 164: 38–53. [PubMed: 29482062]
39. Wang D, Sun Y, Liu Y, Meng F, Lee RJ. Clinical translation of immunoliposomes for cancer therapy: recent perspectives. *Expert Opin Drug Deliv* 2018; 15: 893–903. [PubMed: 30169978]

40. Graziani SR, Vital CG, Morikawa AT, Van Eyll BM, Fernandes Junior HJ, Kalil Filho R et al. Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma. *Med Oncol* 2017; 34: 151. [PubMed: 28756613]
41. Grabbe S, Haas H, Diken M, Kranz LM, Langguth P, Sahin U. Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma. *Nanomedicine (Lond)* 2016; 11: 2723–2734. [PubMed: 27700619]
42. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomized, double-blind, phase 3 trial. *Lancet Oncol* 2014; 15: 59–68. [PubMed: 24331154]
43. Vansteenkiste JF, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J et al. MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the RecMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC). *Ann Oncol* 2014; 25: 409–416. [PubMed: 24368400]
44. Kruit WHJ, Suci S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. *J Clin Oncol* 2013; 31: 2413–2420. [PubMed: 23715572]
45. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2016; 17: 822–835. [PubMed: 27132212]
46. Limentani SA, Campone M, Dorval T, Curigliano G, de Boer R, Vogel C et al. A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. *Breast Cancer Res Treat* 2016; 156: 319–330. [PubMed: 26993131]
47. Berinstein NL, Karkada M, Oza AM, Odunsi K, Vilella JA, Nemunaitis JJ et al. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. *Oncoimmunology* 2015; 4: e1026529. [PubMed: 26405584]
48. Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E et al. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. *Vaccine* 2014; 32: 5901–5907. [PubMed: 25218300]
49. Bavananthasivam J, Alkie TN, Astill J, Abdul-Careem MF, Wootton SK, Behboudi S et al. In ovo administration of Toll-like receptor ligands encapsulated in PLGA nanoparticles impede tumor development in chickens infected with Marek's disease virus. *Vaccine* 2018; 36: 4070–4076. [PubMed: 29859800]
50. Thompson EA, Ols S, Miura K, Rausch K, Narum DL, Spångberg M et al. TLR-adjuvanted nanoparticles vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. *JCI Insight* 2018; 3.pii:120692. [PubMed: 29769448]
51. Zupan E, Curato C, Paisana M, Rodrigues C, Porat Z, Viana AS et al. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming. *J Control Release* 2017; 258: 182–195. [PubMed: 28511928]
52. Salvador A, Igartua M, Hernandez RM, Pedraz JL. Combination of immune stimulating adjuvants with poly(lactide-co-glycolide) microspheres enhances the immune response of vaccines. *Vaccine* 2012; 30: 589–596. [PubMed: 22119926]
53. Lee YR, Lee YH, Im SA, Kim K, Lee CK. Formulation and Characterization of Antigen-loaded PLGA Nanoparticles for Efficient Cross-priming of the Antigen. *Immune Netw* 2011; 11: 163–168. [PubMed: 21860609]
54. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI et al. Programming the magnitude and persistence of antibody responses with innate immunity. *Nature* 2011; 470: 543–547. [PubMed: 21350488]
55. Allahyari M, Mohit E. Peptide/protein vaccine delivery system based on PLGA particles. *Hum Vaccin Immunother* 2016; 12: 806–828. [PubMed: 26513024]

56. Silva AL, Rosalia RA, Varypataki E, Sibuea S, Ossendorp F, Jiskoot W Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation. *Vaccine* 2015; 33: 847–854. [PubMed: 25576216]
57. Saini V, Jain V, Sudheesh MS, Jaganathan KS, Murthy PK, Kohli DV. Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen. *Int J Pharm* 2011; 408: 50–57. [PubMed: 21291968]
58. Feng L, Qi XR, Zhou XJ, Maitani Y, Wang SC, Jiang Y et al. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. *J Controlled Release* 2006; 112: 35–42.
59. Jaganathan KS, Singh P, Prabakaran D, Mishra V, Vyas SP. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B. *J Pharm Pharmacol* 2004; 56: 1243–1250. [PubMed: 15482638]
60. Rosas JE, Pedraz JL, Hernandez RM, Gascon AR, Igartua M, Guzman F et al. Remarkably high antibody levels and protection against *P. falciparum* malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. *Vaccine* 2002; 20: 1707–1710. [PubMed: 11906756]

	Formulation	Size (d.nm) (N = 3)	PDI (N = 3)	Zeta Potential (mV) (N = 3)
1	Blank PLGA-nanoparticles	309 ± 4.01	0.14 ± 0.03	- 0.66 ± 0.25
2	BCMA Peptide loaded PLGA-nanoparticles	257 ± 11.53	0.13 ± 0.01	- 1.16 ± 0.18

	Formulation	Size (d.nm) (N = 3)	PDI (N = 3)
	BCMA Peptide loaded Liposome-nanoparticles	172 ± 0.73	0.20 ± 0.01

Figure 1. Morphology of heteroclitic BCMA₇₂₋₈₀ peptide-encapsulated nanoparticles (PLGA, liposome) and quantification of BCMA₇₂₋₈₀ peptide encapsulation.

A: Scanning electron microscope (SEM) image of gold/palladium sputter-coated BCMA peptide encapsulated PLGA-nanoparticles. Summary of nanoparticle size, PDI and Zeta potential (mV) from three independent experiments (N=3). **B:** Transmission electron microscope (TEM) image of BCMA peptide encapsulated liposome-nanoparticles after applying uranyl acetate as a negative stain. Summary of nanoparticle size and PDI from three independent experiments (N=3). **C:** Quantification of BCMA peptide-FITC loading and encapsulation efficiency based on fluorescence intensity measured at Ex/Em at 390 nm/475 nm. Summary of the average of encapsulation efficiency from three independent experiments (N=3).

Figure 2. Enhanced loading efficiency of heteroclitic BCMA₇₂₋₈₀ peptide encapsulated nanoparticles by immature dendritic cells.

A: Representative flow cytometric analyses of time-dependent (0.5 - 2 hours) uptake of BCMA peptide-FITC by immature dendritic cells, as (1) free peptide, (2) encapsulated in PLGA, or (3) encapsulated in liposome. **B:** A summary of three independent flow cytometric analyses (N=3), showing time-dependent (1 - 18 hours) uptake of BCMA peptide-FITC by immature dendritic cells, as (1) free peptide, (2) encapsulated in PLGA, or (3) encapsulated in liposome. **C:** Representative confocal microscopic analyses of (1) immature dendritic cells alone (no peptide pulsed), (2) immature dendritic cells pulsed with BCMA peptide-FITC, or (3) immature dendritic cells pulsed with BCMA peptide-FITC encapsulated PLGA nanoparticles after pulsing for 18 hours.

Figure 3. Increased immune responses of BCMA-specific CTL induced with BCMA peptide-encapsulated nanoparticles against multiple myeloma cell lines. HLA-A2-restricted anti-myeloma activities of heteroclitic BCMA-specific CTL generated from HLA-A2⁺ normal donor's PBMC by stimulation with (1) free peptide, (2) PLGA/peptide or (3) liposome/peptide. Functional immune activities were assessed by (A) CD107a degranulation, (B) IFN-γ production, (C) IL-2 production, and (D) TNF-α production.

Figure 4. Increased anti-MM activities of BCMA-specific CTL generated with BCMA₇₂₋₈₀ peptide encapsulated nanoparticles against primary CD138⁺ tumor cells from myeloma patients. A: Background functional activities by BCMA-CTL alone (no tumor cells encountered). **B and C:** Anti-MM activities of PLGA/peptide-CTL against primary CD138⁺ tumor cells from (B) HLA-A2⁺ MM Patient #1 or from (C) HLA-A2⁺ MM Patient #2. **D:** Summary of three independent experiments (N=3) showing the HLA-A2 restricted anti-tumor activities of BCMA-CTL against primary CD138⁺ tumor cells from myeloma patients.

Figure 5. Increased frequency of CD28⁺ and Tetramer⁺ CTL, Th1-type cytokine production, and proliferation of CD8⁺ T cells by PLGA/BCMA peptide-CTL.

A: Increased frequency of CD28⁺ (Top Panel) and BCMA-specific Tetramer⁺ CD8 T cells with CD28 upregulation (Bottom Panel) in PLGA/BCMA peptide-CTL. **B:** Increased proliferation (CD8⁺ T cells gated) of PLGA/peptide-CTL in response to heteroclitic BCMA₇₂₋₈₀ peptide in a time-dependent manner (Day 5 > Day 4 > Day 3). **C:** Increased frequency of peptide-specific IFN- γ ⁺ cells (CD8⁺ T cells gated) in PLGA/BCMA-CTL in response to heteroclitic BCMA₇₂₋₈₀ peptide.

Figure 6. Increased memory cells with functional immune activities against myeloma cells in PLGA/BCMA peptide-CTL.

A: Increased CD8⁺ T cell proliferation in the PLGA/BCMA-CTL in response to HLA-A2⁺ U266 MM cells (Day 6 > Day 4). **B:** Increased induction of total CD45RO⁺ memory CTL by PLGA/BCMA peptide than by free peptide, measured post-3, post-4 and post-5 cycles of stimulation. **C:** Summary of three independent experiments (N=3) demonstrating increased memory CTL induction by PLGA/peptide than by free peptide, measured post-2 and post-4 cycles of stimulation. **D:** Increased level of central memory and effector memory CTL generation by stimulation with PLGA/peptide than free peptide, measured post-1 and post-3 cycles of stimulation. Increased maintenance of central memory cells was detected in BCMA-CTL generated by PLGA/peptide than free peptide, measured post-5 cycles of peptide stimulation.

Figure 7. Increased anti-myeloma activities of BCMA-specific memory CTL generated with PLGA/BCMA peptide.

A and B: Increased anti-myeloma activities of BCMA-specific central memory and effector memory CTL generated with PLGA/peptide than free peptide, demonstrated by **(A)** CD107a degranulation and **(B)** IFN-γ production, in response to HLA-A2⁺ myeloma cells (U266).

C: Summary of three independent experiments (N=3) showing increased anti-myeloma activities (CD107a degranulation, IFN-γ/IL-2/TNF-α cytokine production) by PLGA/peptide-induced memory CTL (CM > EM) compared to free peptide-induced memory CTL.